A phase 1, first-in-human, open label, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite nasal spray in healthy adult participants
Stabilized isoamyl nitrite (SIAN) is a novel small molecule, therapeutic candidate for the treatment of cyanide poisoning. SIAN improves survival and has a demonstrated pharmacodynamic (PD) effect in cyanide challenged nonhuman primates. Here, we report results of phase 1, first-in-human study evaluating the safety, tolerability, pharmacokinetic (PK), and PD of SIAN nasal spray in healthy human subjects (NCT05194358). SIAN was intranasally administered in ascending doses at 2 sites in Texas and Tennessee in the United States. A total of 47 subjects were enrolled across 7 dose cohorts evaluating single doses from 20 to 300 μL. Following the dosing of sentinels in each cohort, safety, PK, and PD data were interpreted by a Safety Monitoring Committee to permit dosing of additional subjects in the cohort or escalation to the next dose level. Isoamyl alcohol peak plasma concentrations were reached within 2 minutes and were highest after a 250 μL dose (125 μL/nostril). This trend was also observed for PD parameters, including a metHB peak at 2 minutes with associated increase in heart rate and systolic and diastolic blood pressure. SIAN was generally well tolerated, no serious or severe drug-related effects were observed, and there were no clinically significant changes in vitals or laboratory parameters. We conclude that SIAN, a potential new treatment for cyanide poisoning, was safe, well tolerated, and showed a relationship between PK and PD parameters at the doses tested. SIGNIFICANCE STATEMENT: This is the first-in-human clinical study to evaluate intranasal stabilized isoamyl nitrite, which was shown to be safe, well tolerated, and to elicit a measurable pharmacokinetic and pharmacodynamic response in healthy human subjects at the doses tested. This study paves the way for investigating stabilized isoamyl nitrite further as a potential emergency treatment for cyanide poisoning.
Authors
- Daniel Hill
- Christopher P. Holstege
- William Smith (ORCID: https://orcid.org/0000-0003-1569-0799)
- D.J. Wyatt (ORCID: https://orcid.org/0000-0003-0636-9725)
- Vladimir Savransky (ORCID: https://orcid.org/0000-0002-6458-2690)
- Bojan Drobic (ORCID: https://orcid.org/0000-0001-8139-6446)
- David Cassie (ORCID: https://orcid.org/0000-0002-5360-7768)
- Mila Mirceta
- Jing Tian (ORCID: https://orcid.org/0000-0003-0329-6268)
- Melisa Bellani
- Jessica McLeod (ORCID: https://orcid.org/0009-0003-4669-5100)
- Jeffrey D. Punch
- Vira Artym
- Erika Juanitez
- Vanja Komlenovic
- Bob Warnock
Institutions
- Syneos Health (United States) (US)
- Alliance for Multispecialty Research (United States) (US)
- Emergent BioSolutions (Canada) (CA)
- University of Virginia (US)
Publication Details
- Journal
- Journal of Pharmacology and Experimental Therapeutics
- Published
- 2025-04-17
- DOI
- https://doi.org/10.1016/j.jpet.2025.103584
- Primary Topic
- Poisoning and overdose treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Health and Human Services
- Biomedical Advanced Research and Development Authority